Cooper Q4 2024 Earnings Report
Key Takeaways
CooperCompanies reported strong Q4 2024 results, with revenue reaching $1,018.4 million, a 10% increase year-over-year. GAAP EPS increased by 38% to $0.58, and non-GAAP EPS rose by 19% to $1.04.
Q4 2024 revenue increased by 10% to $1,018.4 million, or 7% organically.
GAAP diluted EPS for Q4 2024 grew by 38% to $0.58.
Non-GAAP diluted EPS for Q4 2024 increased by 19% to $1.04.
CooperVision (CVI) revenue increased by 9% to $676.4 million, with 8% organic growth.
CooperSurgical (CSI) revenue increased by 12% to $342.0 million, with 5% organic growth.
Cooper
Cooper
Cooper Revenue by Segment
Forward Guidance
The Company initiated its fiscal year 2025 financial guidance. Fiscal 2025 total revenue of $4,080 - $4,158 million (organic growth of 6% to 8%). CVI revenue of $2,733 - $2,786 million (organic growth of 6.5% to 8.5%). CSI revenue of $1,347 - $1,372 million (organic growth of 4% to 6%). Fiscal 2025 non-GAAP diluted earnings per share of $3.92 - $4.02
Positive Outlook
- Fiscal 2025 total revenue of $4,080 - $4,158 million (organic growth of 6% to 8%)
- CVI revenue of $2,733 - $2,786 million (organic growth of 6.5% to 8.5%)
- CSI revenue of $1,347 - $1,372 million (organic growth of 4% to 6%)
- Fiscal 2025 non-GAAP diluted earnings per share of $3.92 - $4.02
Revenue & Expenses
Visualization of income flow from segment revenue to net income